CYP2C19 and acute coronary syndrome: In addition, the positive predictive value of CYP2C19 loss-of-function genetic polymorphisms is estimated to be between 12% and 20% in patients who have acute coronary syndrome (ACS) and are undergoing percutaneous coronary interventions (PCIs).